HOME >> MEDICINE >> NEWS
ACTOS (pioglitazone HCl) demonstrates significant improvements in cardiovascular outcomes

Copenhagen, Denmark, September 14, 2006 -- Several abstracts presented today at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) indicated that ACTOS (pioglitazone HCl), an oral antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing the risk of heart attack and/or stroke and acute coronary syndrome in patients with type 2 diabetes. Cardiovascular disease (CVD) is the leading cause of premature death in patients with diabetes. An estimated 171 million people worldwide have diabetes, and CVD is responsible for 50% to 80% of deaths in people with diabetes.

"We are continuing to see the benefits of ACTOS beyond glycemic control," said Erland Erdmann, M.D., chairman of the PROactive Executive Committee and director of the Clinic III for Internal Medicine, University of Cologne, Germany. "We know that patients with diabetes are two to four times more likely to develop heart disease or have a stroke than people without diabetes. The data presented at EASD showed that ACTOS can have a positive effect on several measures of cardiovascular disease outcomes in high-risk patients with type 2 diabetes."

Reduced Occurrence of Major Adverse Cardiovascular Events (MACE)

Results from one of the studies showed that ACTOS significantly reduced the occurrence of major adverse cardiovascular events (MACE), such as heart attacks, nonfatal stroke, acute coronary syndrome and cardiovascular death in high-risk patients with type 2 diabetes. Compared to placebo, patients treated with ACTOS demonstrated statistically significant risk reductions of heart attacks (23 percent, P=0.046), the combined risk of cardiovascular death, nonfatal heart attack or nonfatal stroke (18 percent, P=0.020) and the combined risk of all-cause mortality, nonfatal heart attack, nonfatal stroke or acute coronary syndrome (17 percent, P=0.010). These results were part of the landmark PROactive (PROspectiv
'"/>

Contact: Jocelyn M. Gerst
jgerst@tpna.com
847-769-6889
Ketchum
14-Sep-2006


Page: 1 2 3 4

Related medicine news :

1. ACTOS reduces stroke by almost 50 percent
2. ACTOS (pioglitazone HCl) to be studied in new trial
3. New data shows ACTOS reduced heart attacks by 28 percent in people with type 2 diabetes
4. ACTOS (pioglitazone HCl) significantly improved components of diabetic dyslipidemia
5. ACTOplus met (pioglitazone HCl and metformin HCl)
6. Energy Up demonstrates success as obesity intervention program for inner-city girls
7. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
8. New study demonstrates that Lubiprostone may improve symptom relief rates in adults with IBS-C
9. Research demonstrates link between domestic violence and asthma
10. New study demonstrates nicotines role in smoking behavior
11. Study demonstrates long-term durability of Plicator procedure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/2/2020)... , ... September 02, 2020 , ... ... software for healthcare payers administering Medicare Advantage and Special Needs plans, is proud ... by America’s Health Insurance Plans (AHIP). RAM is supporting the event as a ...
(Date:9/1/2020)... ... September 01, 2020 , ... KitoTech Medical, a ... note financing, which will be used to accelerate the commercialization of its microMend® ... the company will continue to expand its customer base of healthcare systems as ...
(Date:9/1/2020)... ... September 01, 2020 , ... As fall and winter swiftly approach and many ... has taken this time to expand and grow into a full-fledged natural health ... Health Institute will be relaunching its brand new website, expanding its services menu and ...
(Date:8/31/2020)... ... 31, 2020 , ... Cardiothoracic surgeons at Allegheny General Hospital ... Mellon University (CMU) to develop a new heart monitoring device designed to serve ... , The AGH/CMU team was recently awarded a “Trailblazer” grant from the National ...
(Date:8/31/2020)... CHESTER, N.J. (PRWEB) , ... August 31, 2020 , ... Just found out your dear ... cancer.” It’s heartbreaking when your friend or family member shares their diagnosis. Once the shock ... if I say the wrong thing? What are the best ways to help? Words are ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... September 03, 2020 , ... In response to the ... schools and classrooms across the United States, IntraLogic Solutions , a leading ... TEMPE is a non-contact, wall-mounted scanning thermometer that rapidly checks body temperatures. When ...
(Date:9/1/2020)... N.Y. (PRWEB) , ... September 01, 2020 , ... ... dermatologist, and Director of Cosmetics and Laser Surgery at the University of Rochester ... Dermatologic Surgery fellowship at SkinCare Physicians in Boston, with clinical faculty from the ...
(Date:8/31/2020)... ... 31, 2020 , ... Welltech1, the first Israeli VC fund ... $400,000 in PopBase, one of two start-ups that beat 152 companies in the ... , The competition was part of the GWI’s The Wellness Moonshot: A ...
Breaking Medicine Technology:
Cached News: